Furthermore, the offspring of the Tlr9+/+ NOD mice treated with TLR9 antagonist CpG-ODN had significantly delayed and overall lower incidence of diabetes than the progeny of the mice treated with control CpG-ODN (Fig. 6d). Here, TLR9 is linked to diabetes mellitus.